EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

European Patent Office deals blow to pharma companies in dismissing their attempts to reinstate patents covering diabetes and obesity treatments | Inhibrx antibody patent upheld as Gilead subsidiary appeal is rejected.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC dispute resolution forum opens with ceremony in Slovenia

2 June 2026 The court has officially opened its mediation and arbitration forum, with technology, life sciences and manufacturing companies expected to be among its earliest users—particularly in FRAND and licensing cases.

Europe

European court backs AstraZeneca unit in blood cancer combo dispute

28 May 2026 A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.

Europe

Chinese medtech company fined by UPC over injunction breaches

21 May 2026 The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.

More features

Heated LNP litigation puts Moderna and Acuitas in the spotlight

UPC dispute resolution forum opens with ceremony in Slovenia

J&J unit's valuable heart pump saved by 'rare' patent defence

Kirkland & Ellis adds leading barrister in London

Federal Circuit tosses $59m trade secrets judgment against EOFlow

Neal Gerber Eisenberg expands in Chicago with new litigator

European court backs AstraZeneca unit in blood cancer combo dispute

Takeda’s China IP head: What pharma is still getting wrong

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

More on this story

Editor's picks

Editor's picks

More features